HOXB9 is a homeobox-containing gene that plays a key role in mammary gland development and is associated with breast and other types of cancer. Here, we demonstrate that HOXB9 expression is transcriptionally regulated by estradiol (E2), in vitro and in vivo. We also demonstrate that the endocrine disrupting chemical bisphenol-A (BPA) induces HOXB9 expression in cultured human breast cancer cells (MCF7) as well as in vivo in the mammary glands of ovariectomized (OVX) rats. Luciferase assay showed that estrogen-response-elements (EREs) in the HOXB9 promoter are required for BPA-induced expression. Estrogen-receptors (ERs) and ER-co-regulators such as MLL-histone methylase (MLL3), histone acetylases, CBP/P300, bind to the HOXB9 promoter EREs in the presence of BPA, modify chromatin (histone methylation and acetylation) and lead to gene activation. In summary, our results demonstrate that BPA exposure, like estradiol, increases HOXB9 expression in breast cells both in vitro and in vivo through a mechanism that involves increased recruitment of transcription and chromatin modification factors.
Introduction
The members of the homeobox (HOX) containing gene family represent a subset of evolutionarily conserved transcription factors that play crucial roles in embryonic development (Yu et al., 1995; Lappin et al., 2006) . Expression of HOX genes regulate patterning of the anterior-to-posterior axis from the level of the hindbrain to the end of the spine (Hueber and Lohmann, 2008) . However, HOX genes are also expressed in various normal adult tissues (Takahashi et al., 2004; Mallo and Alonso, 2013) . HOXB9, one of the 39 HOX genes, plays key roles in skeletal and mammary gland development (Chen and Capecchi, 1999) . HOXB9 is a direct transcriptional target of WNT/TCF4 (Nguyen et al., 2009) and is involved in cell proliferation, cell-cycle progression, differentiation, embryonic segmentation, limb patterning and angiogenesis (Maeda et al., 2005; Hatzis et al., 2008; Nguyen et al., 2009; Hayashida et al., 2010; Tomioka et al., 2010; Chiba et al., 2012) . Recently it was also shown that HOXB9 expression confers resistance to ionizing radiation indicating its potential roles in the DNA damage response and in maintenance of genomic integrity (Chiba et al., 2012) .
Increasing evidence suggests that altered HOXB9 expression is associated with a variety of cancers, including breast, head and neck, lung, hepatocellular, colon carcinomas and gliomas (Fang et al., 2014; Darda et al., 2015; Sha et al., 2015; Zhan et al., 2015) . HOXB9 overexpression in breast tumors induces breast cancer metastasis by altering the tumor microenvironment, and promotes disease progression (Hayashida et al., 2010) . In fact, HOXB9 expression is an important prognostic factor in breast cancer (Seki et al., 2012) . The overexpression of HOXB9 in breast cancer, and its critical roles in mammary gland development, indicates its potential regulation by endocrine hormones such as estradiol. Indeed recent studies from our laboratory demonstrated that HOXB9 is overexpressed in breast cancer tissues, in ER-positive breast cancer cells and it is transcriptionally regulated by estradiol in cultured MCF7 breast cancer cells (Ansari et al., 2011b; Shrestha et al., 2012) . We also found that HOXB9 regulates the expression of growth and angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor β (TGFβ) etc. and induces three dimensional (3D) tumor colony formation (Shrestha et al., 2012) . The homeodomain of HOXB9 is essential for the transcriptional regulation of tumor growth factors and in 3D colony formation, suggesting the importance of the HOXB9 homeodomain in tumorigenesis (Shrestha et al., 2012) .
Since HOXB9 is found to be overexpressed in breast cancers, aides in tumorigenesis and is transcriptionally regulated by E2, we hypothesized that its transcription may also be affected upon exposure to estrogenic endocrine disrupting chemicals (EDCs) and that may contribute towards HOXB9 associated diseases including breast cancer. Notably, endocrine disruptors are a class of compounds that alters the functioning of the endocrine system and leads to adverse health effects and is a major health concern (Schonfelder et al., 2002a; Fernandez and Russo, 2010; Abdel-Rahman et al., 2012; Fucic et al., 2012; Singh and Li, 2012; Sengupta et al., 2013) . In the present study, we analyzed the impact of a well-known estrogenic EDC, bisphenol-A (BPA) (and also estradiol (E2)) in transcriptional regulation of HOXB9 gene in vitro and in vivo. Notably, BPA is major environmental and health concern due to its ubiquitous presence in the environment and its chronic human exposure (Murray et al., 2007) . BPA is commonly used for manufacturing polycarbonate plastics and epoxy resins, in the inner lining of the food and beverage containers, dental sealants and others (Brotons et al., 1995; Olea et al., 1996; Biles et al., 1997; Fernandez and Russo, 2010) . BPA has been detected in varying concentrations in maternal and fetal plasma, placental tissue and in human urine samples (Ikezuki et al., 2002; Schonfelder et al., 2002b; Calafat et al., 2005) . Numerous studies indicate that low levels of BPA exposure imposes human health risks. Exposure to BPA induces developmental changes in the female reproductive tract and alters mammary gland development in vivo (Murray et al., 2007) . Importantly, fetal exposure to low doses of BPA has been linked with long-lasting effects in the mouse mammary gland that are manifested during postnatal stages. These include increased number of estrogen-receptor and progesterone receptor-positive cells at puberty and increased lateral branching, and development of ductal hyperplasias at postnatal days (in rats) (Murray et al., 2007 ) (Munoz-de-Toro et al., 2005 . The increased number of intraductal hyperplasia in the mammary gland is considered to be linked with precursors of carcinomas both in rodents and humans (Ernst et al., 2004) . Thus, chronic exposure to BPA, even at low levels, is a major health concern to human. Here, our results demonstrate that HOXB9, which is a critical player in mammary gland development and breast cancer, is upregulated upon exposure to BPA in breast cancer cells in vitro and in vivo.
Experimental procedure
Cell culture and treatment with estradiol (E2) and BPA Estrogen receptor (ER) positive MCF7 breast carcinoma cells were purchased from the American Type Cell Culture Collection (ATCC) and cultured as described previously (Bhan et al., 2013; Bhan et al., 2014a; Bhan et al., 2014b; Hussain et al., 2015) . Treatment of MCF7 cells with E2 and BPA was carried out (Bhan et al., 2013; Bhan et al., 2014a; Bhan et al., 2014b; Darda et al., 2015; Hussain et al., 2015) by growing the cells in phenol red-free DMEM-F12 media containing 10 % charcoal stripped FBS for at least three generations. Cells (60-70 % confluent) were then grown in 60 mm cell culture plates and treated with varying concentrations of E2 (0 -100 nM) and BPA (0 -1000 nM) for 6 h. The control (treated with diluent DMSO) and treated MCF7 cells were harvested for RNA/protein extraction as well as for ChIP assays as needed (Ansari et al., 2011b; Ansari et al., 2012a; Shrestha et al., 2012; Ansari et al., 2013b; Bhan et al., 2014b; Hussain et al., 2015) .
RNA extraction, cDNA synthesis, RT-PCR and RT-qPCR
Total cellular RNA and protein were isolated as described previously (Ansari et al., 2008; Ansari et al., 2011b; Bhan et al., 2013; Bhan et al., 2014a; Bhan et al., 2014b; Hussain et al., 2015) . The isolated RNA pellets were air-dried, dissolved in DEPC treated water containing 0.5 mM EDTA and quantified using a Nanodrop spectrophotometer. Synthesis of cDNA was carried out and each cDNA product was diluted to 100 μL, and 5 μL of the diluted cDNA was subjected to RT-qPCR or regular RT-PCR amplification using specific primer pairs described in Table 1 . Regular RT-PCR reactions were carried out for 33 cycles (30 s at 94 °C for denaturation, 30 s at 60 °C for annealing, 45 s at 72 °C for elongation) and the PCR products analyzed by 1.5 % -2 % agarose gel electrophoresis. For the RT-qPCR reactions, 5 μL of diluted cDNA were mixed with 5 μL of Sso EvaGreen supermix (Bio-Rad) and 2 μM of each primer and final volume was made up to 12 μL. PCR reactions were carried out in CFX96 real-time detection system (Bio-Rad) for 40 cycles (5 s at 95 °C for denaturation and 10 s at 60 °C for both annealing and elongation). Data analyses were performed using CFX manager software (Bio-Rad). Each experiment was repeated three times with three replicates each time.
Chromatin Immunoprecipitation assay (ChIP assay)
For ChIP analyses, MCF7 cells were treated with 1 nM E2 or 100 nM BPA for 6 h as described previously by us (Ansari et al., 2008; Ansari et al., 2011b; Bhan et al., 2013; Bhan et al., 2014a; Darda et al., 2015; Hussain et al., 2015) . In brief, 6 h post E2 or BPA treatment, cells were crosslinked with 1% formaldehyde for 10 min at 37 °C, washed twice in ice-cold PBS containing 1 mM PMSF; and 1 X protease inhibitor cocktail (SigmaAldrich) and harvested using SDS lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris, pH 8.1). The harvested cells were subjected to sonication to shear the chromatin (150-450 bp in length). The fragmented chromatin was pre-cleared with protein-G agarose beads and subjected to immunoprecipitation using antibodies specific to ERα (Santa Cruz; 2Q418), ERβ (Santa Cruz; SC-8974), H3K4-trimethyl (EMD-Millipore; 07-473), RNAPII (Abcam; ab5408), MLL3 (Abgent; AP6184a), CBP (Santa Cruz,sc-369), p300 (Santa Cruz; sc-585), N-CoR (Santa Cruz; sc-1609), histone-acetylation (EMD-Millipore; 06-599) and β-actin (Sigma, A2066). Immunoprecipitated chromatin was washed, de-crosslinked and deproteinized at 65 °C in presence of 5 M NaCl, followed by incubation with proteinase K (Sigma) at 45 °C for 1 h. Purified ChIP DNA was PCR amplified using primers spanning ERE4 present in the HOXB9 promoter (Table 1 ). The analysis of ChIP DNA was carried out via regular PCR and qPCR using appropriate primers (Table 1) .
Dual luciferase reporter assay
For ERE luciferase assays, HOXB9 promoter DNA containing the estrogen response elements ERE1 (−6 to −393nt), ERE2 (−999 to −1316 nt), ERE3 (−1174 to −1492 nt), and ERE4 (−1430 to −1858 nt) regions were inserted upstream of the luciferase gene in the pGL3-promoter vector (Promega) ( Table 1 ). MCF7 cells were co-transfected with 1500 ng of construct DNA and 150 ng of a reporter plasmid containing renilla luciferase gene (pRLTk, Promega), as an internal transfection control, using FuGENE6 transfection reagent. MCF7 cells transfected with empty pGL3 served as an experimental control. Twenty-four hours post transfection, the cells were treated with 100 nM BPA for 6 h and then subjected to luciferase assay, using Dual luciferase reporter assay kit (Promega) as instructed by the manufacturer's protocol. Luciferase activities were normalized to the renilla and plotted. Each treatment was performed in four parallel replicates and the experiment was repeated at least twice (Ansari et al., 2009a; Ansari et al., 2009b; Ansari et al., 2011a; Ansari et al., 2011b; Ansari et al., 2012a; Ansari et al., 2012b; Bhan et al., 2013; Bhan et al., 2014a; Bhan et al., 2014b) .
Animal studies
Subjects-Ninety day old, experimentally naïve, adult, female Sprague Dawley rats (n=12) were triple housed and maintained in a temperature and humidity-controlled environment under a 12 h reversed light/dark cycle with lights on at 7 p.m. and off at 7 a.m. All animals were maintained and cared for in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The University of Texas at Arlington's Animal Care and Use Committee approved all experimental procedures and protocols. Notably, all the animals were maintained under equivalent caging, bedding, food, and water bottles conditions to normalize the effects of any exogenous estrogen source on our results. Ovariectomy: Female rats were anesthetized with 2-3% isoflurane-oxygen vapor mixture and ovariectomized (OVX) as previously described by us (Bhan et al., 2014a) and others (MacLusky et al., 2005; Betancourt et al., 2010; Eilam-Stock et al., 2012) . The animals were allowed to recover for 4-5 days post-surgery, daily vaginal lavage testing was performed for 8 consecutive days to confirm cessation of estrous cycling, thus verifying the completion of the OVX procedure. All OVXs performed were confirmed complete and thus, no animals were eliminated on the basis of an incomplete procedure. Acute treatments with E2 and BPA: 10 mg of BPA was dissolved in 1 mL of ethanol to create a stock solution that was stored at −4 °C. E2 was dissolved in peanut oil to yield final concentrations of 5 μg/mL. BPA was dissolved in ethanol and brought up to a final concentration of 50 μg/mL with saline. Rats were given subcutaneous injections of either BPA (25 μg/kg) or E2 (5 μg/kg), (n = 4) 24 and 4 h prior to sacrifice. Animals were sacrificed via rapid decapitation and mammary gland tissue was collected from each rat and flash frozen on dry ice and then stored at −80 °C until RNA extraction (MacLusky et al., 2005; Betancourt et al., 2010; Eilam-Stock et al., 2012) .
RNA extraction from the mammary glands-RNA extraction was carried out using ZyGEM kit (Hamilton, New Zealand) according to the manufacturer's protocol (Ansari et al., 2013b) . The RNA was reverse transcribed and subjected to RT-qPCR and regular RT-PCR using rat specific primers (Table 1) .
Results

HOXB9 is overexpressed in breast and other types of cancer
To investigate the association of HOXB9 with different types of cancer, we first analyzed the cancer genome databases using the cbioportal (http://www.cbioportal.org/public-portal/) data analysis tool, (Cerami et al., 2012; Gao et al., 2013) . This analysis found that the HOXB9 gene is amplified, mutated or deleted in various cancers but primarily in breast, cervical, ovarian, uterine and prostate (Figure 1) . Amplification of HOXB9 gene was observed in 10.3 %, 5.4 % and 4.1 % of the analyzed cases of breast carcinoma. HOXB9 amplification was also observed in 4 % of ovarian and 2 % of prostate cancer cases. Overexpression of HOXB9 in breast cancer tissues is in agreement with our previous findings and studies from other laboratories (Ansari et al., 2011b; Seki et al., 2012) . The overexpression of HOXB9 in breast, prostate, uterine and ovarian tissues suggests potential regulation by steroid hormones and a potential target for mis-regulation by endocrine disrupting chemicals.
HOXB9 is induced by BPA in breast cancer cells and in the mammary gland tissue of ovariectomized (OVX) rats
To understand the potential impacts of estrogenic EDCs on HOXB9 gene regulation, we treated ER-positive MCF7 breast cancer cells with varying concentration of a well-known estrogenic EDC, bisphenol-A (BPA) and analyzed its impacts on HOXB9 gene expression. Additionally, we also treated MCF7 cells with estradiol (E2) as a positive control. Total cellular RNA was isolated, reverse transcribed and the levels of HOXB9 mRNA measured by regular RT-PCR and RT-qPCR, using primers specific to HOXB9 (Table 1) and GAPDH expression as a control. Both BPA and E2-treatment induced HOXB9 mRNA expression in a dose dependent manner (Figures 2A-D) . Notably, HOXB9 expression increased by about 6.6 fold at 1 nM E2 and 9.4 fold at 100 nM BPA, respectively. Since HOXB9 is optimally induced in breast cancer cells by 1 nM E2 and 100 nM BPA, we used these E2 and BPA concentrations for future biochemical experiments. Time-dependent analysis showed that HOXB9 induction in MCF7 cells was similarly optimal at 6 h post-treatment with either 1 nM E2 or 100 nM BPA (data not shown). Additionally, in order to understand the impacts of BPA exposure in the presence of E2, we treated MCF7 cells with varying concentrations of BPA in the presence and absence of E2 (1 nM) and analyzed their impacts on HOXB9 expression. As seen in figure 2 (panels E-F), low concentrations of BPA has nominal impacts on E2-induced HOXB9 expression. However at higher concentrations (100 nM) of BPA, the level of E2-induced HOXB9 is decreased in comparison to E2 alone and this might be likely due to the competition between BPA and E2 for same binding sites on ER. The induction of HOXB9 expression by E2 and BPA in ER-positive breast cancer cells (MCF7) indicate that HOXB9 is transcriptionally regulated by E2 and is potentially misregulated upon exposure to estrogenic EDC like BPA.
To evaluate the impact of BPA on HOXB9 expression in vivo, we treated overiectomized (OVX) Sprague Dawley rats with BPA, as well as E2, and analyzed the impact on HOXB9 mRNA expression in mammary glands. Female Sprague Dawley rats were subjected to ovariectomy, to minimize the impacts of endogenous esrogens and then were subcutaneously injected twice with E2 (5 μg) and BPA (25 μg) 24 h and 4 h before sacrifice. These doses of E2 and BPA treatment were previously used and shown to affect gene expression and impact behavioral traits and other neural functions (Bhan et al., 2014a; Bhan et al., 2014b; Bobzean et al., 2014) . Control OVX rats were treated with the diluent peanut oil (vehicle). Total RNA from mammary glands of control and E2/BPA treated rats was isolated and analyzed by qPCR and regular RT-PCR. Analysis showed that E2 and BPA treatments increased HOXB9 mRNA levels, in the rat mammary glands by ~4 and ~5 fold, respectively, (Figures 2E-F) . These observations suggested that HOXB9 expression is transcriptionally regulated by E2 in the mamarry glands and it is also up-regulated upon exposure to BPA, in vivo.
HOXB9 promoter EREs are responsive to BPA
Since HOXB9 is an E2-responsive gene and is induced by BPA, we investigated the potential mechanism of BPA-induced HOXB9 expression. The HOXB9 promoter contains several putative estrogen-response elements (EREs) (Ansari et al., 2011b) . In the presence of E2, estrogen-receptors (ERs) are activated which in turn bind to EREs present in the promoters of E2-regulated genes and induce transcription (Nilsson and Gustafsson, 2000; Nilsson and Gustafsson, 2002; Lee et al., 2006; Mo et al., 2006) . ERs aid in the recruitment of various ER-co-regulators and epigenetic modifiers to the gene promoters that facilitate histone modification and chromatin remodeling leading to target gene activation (Nilsson et al., 2001; Nilsson and Gustafsson, 2002; Barkhem et al., 2004; Chen et al., 2004) . Promoter analysis revealed that there were three ERE half sites (GGTCA) located at −208 nt, −1201 nt and −1395 nt upstream of the HOXB9 transcriptional start site (TSS) ( Figure 3A ). There is also an imperfect ERE (TGTCCnnnGGTCA) located at −1600 nt ( Figure 3A) that is 1 nt different from the consensus full ERE (GGTCAnnnTGACC) and ERE-half sites are flipped within the palindrome. Given the sequence homology to the consensus ERE, we examined the BPA (and E2) responsiveness of each ERE (ERE1-ERE4) site using a luciferase based reporter assay (Ansari et al., 2011b) . Initially, we cloned each ERE along with ~150 nt of flanking sequences on both sides into a luciferase expression construct, pGL3 ( Figure 3A ) (Ansari et al., 2011b) . A promoter region without an ERE (non-ERE) sequence was also cloned and used as a negative control. Each ERE-pGL3 construct was transfected into MCF7 cells separately, and the cells were exposed to E2 (1 nM) or BPA (100 nM) for 6 h. An empty pGL3 vector was also transfected as a negative control. The cell extracts from the control and (E2/BPA) treated MCF7 cells were subjected to luciferase analysis using a commercial luciferase detection kit (normalized to renilla expression). Our results demonstrated that E2 or BPA treatment of ERE4-pGL3 (which is the imperfect ERE) transfected MCF7 cells resulted in a ~3 and ~4 fold increase in luciferase activity whereas none of the other ERE-GL3 construct displayed any responsiveness to E2 or BPA. Therefore, the ERE4 element, which is an imperfect full ERE, is likely the E2/BPA responsive ERE and may also be associated with BPA-induced HOXB9 expression.
Estrogen-receptors (ERs) and ER co-regulators are enriched at the HOXB9 promoter upon treatment with BPA As ERs are key players in transcriptional up-regulation of estrogen-responsive genes (Nilsson and Gustafsson, 2000; Nilsson and Gustafsson, 2002) , we examined if ERα participates in BPA-induced HOXB9 expression. We examined if BPA and E2 treatment results in recruitment of ER to the HOXB9 promoter, especially the ERE regions, using a chromatin immunoprecipitation (ChIP) assay (Ansari et al., 2011b) . Along with ER, ER coregulators also play key roles in E2-induced gene regulation (Nilsson et al., 2001; Nilsson and Gustafsson, 2002; Barkhem et al., 2004) . Therefore, along with ERα, we also examined selected ER-co-regulators (MLL3, CBP/p300 and N-CoR) for enrichment at the HOXB9 promoter upon treatment with BPA or E2 (Dreijerink et al., 2006; Lee et al., 2006; Mo et al., 2006) . Notably, MLLs are well-recognized histone methyl-transferases that specifically introduce histone H3 lysine-4 (H3K4) methylations and regulate gene activation (Barkhem et al., 2004; Ernst et al., 2004; Hess, 2004; Guenther et al., 2005; Ansari et al., 2009b; Ansari et al., 2009c; Lee et al., 2009; Ansari and Mandal, 2010; Mandal et al., 2010; Ansari et al., 2011a; Ansari et al., 2011b; Bhan et al., 2013) MLLs are recently implicated in estradiol/BPA induced gene activation (Ansari et al., 2009b; Ansari et al., 2011a; Ansari et al., 2011b; Bhan et al., 2013; Bhan et al., 2014a; Bhan et al., 2014b) . In particular, our previous studies indicated involvement of MLL3 in HOXB9 gene regulation (Ansari et al., 2011b) and therefore, here we investigated the potential involvement of MLL3 in BPAinduced HOXB9 regulation. CBP and p300 are well known histone acetyl-transferases that play crucial roles in NR-mediated gene activation (Bulynko and O'Malley, 2011; Ansari et al., 2013a) . N-CoR is a repressive NR-coregulator that maintains the repressive state of gene in the absence of activated or liganded ERs (Shibata et al., 1997; Oesterreich et al., 2000; Jiang et al., 2006) . Here, we examined the E2/BPA-dependent recruitment of ERs and ERcoregulators (MLL3, CBP/p300 and N-CoR) at the ERE4-region of HOXB9 promoter (Figure 4) because it was the ERE regulating E2/BPA-treatment response in the luciferase analysis ( Figure 3B ). In brief, MCF7 cells were treated with E2 (1 nM) and BPA (100 nM) for 6 h, fixed with formaldehyde, sonicated to shear the chromatin and then subjected to immunoprecipitation using ERα, MLL3, CBP, p300 and N-CoR specific antibodies. β-actin antibody was used as a non-specific antibody control. The immunoprecipitated DNA fragments were purified and PCR-amplified using primers spanning the HOXB9 promoter ERE4 region (also in other ERE, see Figure S1 ) (Figures 4B-C) . ChIP analysis showed that ERα, MLL3, CBP and p300 were enriched in the ERE4 region in the presence of either BPA or E2 (Figures 4B-C) . Beyond ERE4, we also found some amount of enrichment of ERα, MLL3, CBP and p300 in the ERE3 region while no significant binding were observed in the ERE1, ERE2 and the non-ERE regions ( Figure S1 ). No significant binding of β-actin was observed at the HOXB9 promoter (used as a non-specificity control, Figures 4B-C ). These observations demonstrate that, along with ERs, ER-coregulators such as histone methylase MLL3 and histone acetylases, CBP and p300, bind to HOXB9 promoter ERE (primarily ERE4) in a BPA-dependent manner and regulate BPA induced HOXB9 expression. We also found that the occupancy levels of nuclear receptor co-repressor (N-CoR) were significantly reduced at the HOXB9 promoter upon treatment with either E2 or BPA.
MLLs are well known H3K4-specific methyl-transferases and CBP/P300 are histone acetylases (Strahl and Allis, 2000; Martin et al., 2003; Bannister and Kouzarides, 2004; Hess, 2004; Guenther et al., 2005; Crawford and Hess, 2006) . Since MLL3, CBP/p300 were enriched at the HOXB9 promoter in a BPA/E2-dependent manner, we examined the levels of histone acetylation and histone H3K4-tri-methylation in the HOXB9 promoter in the absence and presence of BPA, using ChIP assay. We also analyzed the recruitment of RNA Polymerase II (RNAP II) to the HOXB9 promoter in the absence and presence of BPA. Our ChIP analyses demonstrated that the levels of histone H3K4-trimethylation, histone acetylation and the levels of RNA polymerase II were increased at the HOXB9 promoter (ERE4) in the presence of BPA or E2 (Figures 4B-C) . The enrichment of histone methylases (MLL3) and histone acetylases (CBP, p300) and consequent increase in H3K4-trimethylation and histone acetylation at the HOXB9 promoter in presence of BPA, suggest the potential involvement of these ER-coregulators in the BPA mediated transcriptional activation of HOXB9. The BPA/E2-induced dissociation of N-CoR from the HOXB9 promoter suggests its potential involvement in the maintenance of the basal level HOXB9 transcription, especially in the absence of any stimuli such as E2 or BPA.
Discussion
HOXB9 is a critical player in skeletal and mammary gland development (Chen and Capecchi, 1999) . Mice homozygous for HOXB9 mutation show developmental defects and a significant decline in newborn survival (Chen and Capecchi, 1997) ; it also leads to abnormal breast epithelium branching and lobulo-alveolar development, eventually leading to the inability of the mother to nurse pups (Chen and Capecchi, 1999) . In addition to its critical role in mammary gland and skeletal development, HOXB9 is involved in regulation of renin and hence regulates blood pressure, fluid homeostasis, and electrolyte balance (Pan et al., 2001 ). Recent studies demonstrate that HOXB9 is overexpressed in 42% of human breast tumors (Hayashida et al., 2010) . Furthermore, HOXB9 is a homeodomain containing transcription factor, and is involved in regulation of tumor growth and angiogenic factors and hence plays critical roles in tumorigenesis and metastasis (Hayashida et al., 2010; Shrestha et al., 2012) . Studies from our laboratory demonstrated that HOXB9, through it homeodomain, binds to the promoters of tumor growth and angiogenic factors like NRG2 (neuregulin-2), VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), TGFβ-1 (tumor growth factor β-1) control 3D tumor colony formation (Shrestha et al., 2012) . Furthermore, we demonstrated that HOXB9 expression is transcriptionally induced by E2, in cultured breast cancer cells (Ansari et al., 2011b) . As HOXB9 is overexpressed in breast cancer, and is involved in mammary gland development and is transcriptionally regulated by estradiol in breast cancer cells, here, we investigated its potential endocrine disruption by estrogenic EDCs such as BPA, in vitro and in vivo.
Additionally, we also analyzed the expression levels of HOXB9 in different types of cancers using publicly available cancer genome database, using Cbioportal data analysis software (Cerami et al., 2012; Gao et al., 2013) . This analysis demonstrated that HOXB9 gene is amplified, mutated and deleted in variety of cancer cells (Figure 1) . Specifically, amplification of HOXB9 gene was observed in several analyzed cases of breast, ovarian and prostate cancer. The overexpression of HOXB9 in endocrine regulated tumors such as breast, prostate and ovarian cancers, indicates its potential regulation by endocrine hormones such as estrogens and androgens and furthermore makes it a potential target of endocrine disruption upon exposure to hormone mimicking EDCs such as BPA.
To investigate the potential endocrine disruption of HOXB9, we exposed both cultured breast cancer cells as well as OVX female Sprague Dawley rats with BPA (as well as E2 as control) and analyzed their impacts of HOXB9 expression. Our analysis demonstrated that HOXB9 mRNA expression is not only induced by E2 but also by BPA, both in vitro (cultured MCF7 cells) and in vivo (mammary glands of OVX rats), indicating its transcriptional regulation by E2 and its potential endocrine disruption upon exposure to estrogenic EDCs like BPA and others. Notably, ERs and ER-coregulators are integral components of estrogen-dependent gene activation and signaling. During estrogendependent gene activation, upon binding of the ligand to estrogen-receptors (ERs), ERs undergo conformational changes, and bind to estrogen-response-elements (EREs) present in the promoters of estrogen responsive genes, resulting in their transcriptional activation. Along with ERs, variety of ER-coactivators also coordinate with the estradiol-dependent gene activation and signaling (Brzozowski et al., 1997; Feng et al., 1998; Paige et al., 1999; Ansari et al., 2011b) . These co-regulators usually possess enzymatic activity, modify chromatin, and bridge ERs with transcription machinery (Chen et al., 2004; Mo et al., 2006) . Many ER-coactivators have been identified including SRC-1 family of protein, CREB binding protein (CBP/p300), p/CAF, ASCOM (activating signal cointegrator-2 that also contains MLLs), etc (Mangelsdorf et al., 1995; Lee et al., 2001; Dreijerink et al., 2006; Lee et al., 2009 ). Sequence analysis demonstrated that HOXB9 promoter contains multiple ERE1/2 sites (ERE1-3) and a potential imperfect full ERE (ERE4) (Nilsson and Gustafsson, 2002) . Based on our luciferase based reporter assay, we observed that not only E2 but also BPA response induces HOXB9 promoter activity. ERE4, which is an imperfect full ERE, showed significant induction of luciferase activity in response to both E2 and BPA exposure, indicating its potential involvement in estrogen-mediated gene expression and endocrine disruption by BPA.
ChIP analyses demonstrate that ERα and a variety of ER-coregulators such as histone methylase, MLL3, and histone acetylases, CBP and p300 are enriched at the HOXB9 promoters during E2 as well as BPA-induced HOXB9 expression. Notably, MLL-family of histone methylases is a well-known family of H3K4-specific methyl-transferases that play key roles in gene activation (Strahl and Allis, 2000; Martin et al., 2003; Bannister and Kouzarides, 2004; Hess, 2004; Guenther et al., 2005; Crawford and Hess, 2006) . Studies from our laboratory and others have shown that MLLs functionally coordinate with ERsduring estrogen-dependent gene activation (Ansari et al., 2009b; Ansari et al., 2011a; Ansari et al., 2013a; Ansari et al., 2013b; Bhan et al., 2013; Bhan et al., 2014a; Bhan et al., 2014b; Hussain et al., 2015) . MLLs are a novel class of ER-coregulators. Here, our analysis further demonstrated that histone methylase, MLL3 coordinates with the E2 and BPA-induced HOXB9 gene activation. Notably, the involvement of MLL3 in E2-induced HOXB9 activation is in agreement with our previous observation (Ansari et al., 2011b) . ER-mediated recruitment of histone methylases and acetylases at the ER-target promoters, are anticipated to modify histone proteins, remodel the chromatin, which ultimately contribute to gene activation. Indeed, our ChIP analysis also showed that BPA (as well as E2) treatment increased the epigenetic marks of histone H3K4-trimethylation, and histone acetylation, and increased RNA polymerase II enrichment at the HOXB9 promoter region (ERE4). We also observed that NCoR, a nuclear receptor co-repressor, is localized at the HOXB9 promoter in the absence of E2 or BPA-treatment and is delocalized following exposure to either E2 or BPA, indicating the potential role of NCoR in maintenance of basal transcription of HOXB9.
Involvement of ERs and ER-coregulators as well as changes in histone modifications upon BPA-induced HOXB9 gene activation, indicate that the epigenetic mechanism of transcriptional activation of HOXB9 by BPA is similar to that of estradiol-mediated HOXB9 activation (a model showing the mechanism of BPA induced endocrine disruption of HOXB9 is shown in figure 5 ). These observations also further indicate that HOXB9 gene expression may be disrupted upon exposure to estrogenic EDCs like BPA and others both in vitro and in vivo, even in the absence of estradiol, and that may contribute towards abnormal HOXB9 expression and various human pathogenesis including breast cancer. Notably, EDCs are classes of molecules when exposed to our body, they interact with various hormone receptors at very low concentrations and alter the hormone signaling pathways affecting various hormonally regulated processes including reproduction and development (Richter et al., 2007) . Chronic and/or acute exposure to EDCs results in harmful health effects including birth defects, diabetes, cancers, reproductive problems, early puberty, and obesity (Fernandez and Russo, 2010; Abdel-Rahman et al., 2012; Fucic et al., 2012; Singh and Li, 2012; Sengupta et al., 2013) . Exposure to EDCs results in alteration in the gene expression profiles. For example, exposure to estrogen mimicking EDCs such as bisphenol-A (BPA) alters uterine HOX gene expression and induces developmental changes in the female reproductive tract (Schonfelder et al., 2002a) . BPA is commonly found in plastics, metallic storage containers, and other routinely used consumables (Fernandez and Russo, 2010) . It is widely used since 1950 as a monomer that is polymerized to manufacture polycarbonate plastic and epoxy resins and found as an environmental contaminant (Fernandez and Russo, 2010) . The impacts of BPA exposure on human health have been extensively studied. Exposure to BPA leads to developmental and reproductive anomalies (Schonfelder et al., 2002a) . Perinatal exposure to BPA alters mammary gland development in vivo (Schonfelder et al., 2002a) . BPA exposure has also been shown to alter the epigenetic states at the cellular level and that may be transmitted through multiple passages post BPA exposure. In particular, a study by Weng et al, showed that low-dose BPA treatment to breast epithelial cells (progenitor cells) induced epigenetic changes that were transmitted to their differentiated progeny through various epigenetic mechanisms even when the cells were not exposed to BPA at the differentiation stages (Weng et al., 2010) . Low-dose BPA exposure to breast epithelial progenitor cells induced nuclear internalization of ERα and affected ERsignaling pathways and ER-target genes expression. Upon exposure to BPA, the expression of lysosomal-associated membrane protein 3 (LAMP3) became epigenetically silenced via promoter CpG-island methylation, in breast epithelial cells (Weng et al., 2010) . Similarly, an independent study by Qin et al examined the effect of BPA on cellular proliferation and senescence in human mammary epithelial cells (HMEC) (Qin et al., 2012) . These studies demonstrated that BPA exposure at an early passage stage increased the proliferation and the sphere size of HMEC up to passage 16. Briefly, early exposure to BPA induced epigenetic alterations in the form of epigenetic memory and that were transmitted for several generations (passages) even in the absence of BPA. The results of BPA-induced epigenetic alterations include increased protein levels of p16 and cyclin E, which are known to induce cellular senescence and promote proliferation, respectively. Furthermore, DNA methylation levels of genes related to development of most or all tumor types, such as BRCA1, CCNA1, CDKN2A (p16), and others, were increased in BPA-exposed HMEC. These observations suggest that BPA has the capability to modulate cell growth in breast epithelial cells via modulation of the epigenetic states and these nay be heritable and may contribute to abnormal mammary development and in mammary carcinogenesis (Qin et al., 2012) . Thus, exposure to BPA is of serious health concern. In the present study, we demonstrated that breast cancer (as well as variety of other cancers) associated gene HOXB9, is upregulated upon exposure to BPA both in vitro and in vivo. Even in the absence of native hormone estradiol, BPA activates estrogen-receptors, that in turn, activates and recruits variety of ERcoregulators at the HOXB9 promoter, alters the promoter histone modification and other epigenetic features resulting in HOXB9 gene induction which is associated with breast and other carcinogenesis. Thus our studies demonstrate that BPA is an estrogenic EDC and therefore its exposure is capable of altering the epigenetic programming in cells causing unwanted gene activation and that may contribute towards increased risk of cancer and other human diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Cross-cancer analysis of copy number alterations and mutations in HOXB9 based on cBioPortal database (Cerami et al., 2012; Gao et al., 2013) HOXB9 promoter EREs are responsive to BPA treatment. (A) HOXB9 gene promoter EREs, termed as ERE1, ERE2, ERE3 and ERE4 locations and the neighboring sequences are shown in panel A. The promoter regions spanning the EREs were cloned into luciferase based reporter construct, pGL3 and used for luciferase assay (cloned region for each ERE is shown in panel A). (B) Luciferase based reporter assay. ERE containing pGL3 constructs or empty pGL3 (control vector) constructs were co-transfected into MCF7 cells along with renilla luciferase construct (pRLTK; internal transfection control) for 24 h. Cells were then treated with 100 nM BPA and 1 nM E2 for 6 h and then subjected to luciferase assay by using dual-Glo Luciferase Assay kit. The luciferase activities (normalized to renilla activity) were plotted. The experiment was repeated thrice with four parallel replicates (n =3). Bars indicate standard errors. P values ≤ 0.05 were considered to be significant. E2 and BPA-dependent recruitment of ER and ER-coregulators at the HOXB9 promoter. (A-C): MCF7 cells were treated with 1 nM E2 and 100 nM BPA, separately for 6 h and subjected to ChIP assay using antibodies specific to MLL3, CBP, p300, H3K4me3, histone acetyl, RNAP II, N-CoR and β-actin (negative control). ChIP DNA fragments were PCRamplified and analyzed by qPCR and regular PCR using primers specific to ERE4 region of the HOXB9 promoter. Panel A shows the position of the primer spanning ERE4 region in the HOXB9 promoter. Panels B-C show the ChIP analyses of MLL3, CBP, p300, H3K4-trimethyl marks, histone acetyl marks, RNAP II, N-CoR and β-actin on the ERE4 of the HOXB9 promoter. Each experiment was repeated at least thrice. Bars indicate standard errors. P values ≤ 0.05 were considered to be significant. Model showing the roles of ER, MLL and other ER-coregulators in E2 and BPA-mediated upregulation of HOXB9. During classical E2-stimulated HOXB9 gene expression, ERs dimerize upon binding to E2, dimerized ERs translocate into the nucleus and bind to the EREs present in the promoter region of HOXB9. ER-coregulators such as MLL3, CBP, p300, and other ER-coregulators are also recruited to the HOXB9 promoter. Promoter histones are methylated via MLL3 and acetylated via the catalytic activity of CBP/p300 and thus allowing access to RNA polymerase II (RNAP II) and other GTFs to the promoter (Chen et al., 2004) , ultimately leading to transcriptional activation of HOXB9. Exposure of cells to estrogen mimicking endocrine disrupting chemicals (EDCs) such as BPA that in turn competes with endogenous E2 and binds to ERs, leading to activation of ERs and associated ER-target gene activation, in a fashion very similar to E2. Thus, even in the absence of E2, BPA can induce ER-target genes such as HOXB9 leading to their misregulation.
